June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Lipoxin B4, a Novel Neuroprotectant for the Inner Retina.
Author Affiliations & Notes
  • John G Flanagan
    School of Optometry, University of California Berkeley, Berkeley, California, United States
  • Hsin-Hua Liu
    School of Optometry, University of California Berkeley, Berkeley, California, United States
  • Karsten Gronert
    School of Optometry, University of California Berkeley, Berkeley, California, United States
  • Jeremy M Sivak
    Vision Sciences and Ophthalmology, University of Toronto, Toronto, Ontario, Canada
  • Izzy Livne-Bar
    School of Optometry, University of California Berkeley, Berkeley, California, United States
    Vision Sciences and Ophthalmology, University of Toronto, Toronto, Ontario, Canada
  • Footnotes
    Commercial Relationships   John Flanagan, Carl Zeiss Meditec (C), Carl Zeiss Meditec (F), EyeCarrot Inc (S); Hsin-Hua Liu, None; Karsten Gronert, None; Jeremy Sivak, None; Izzy Livne-Bar, None
  • Footnotes
    Support  Canadian Institutes of Health Research
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2575. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      John G Flanagan, Hsin-Hua Liu, Karsten Gronert, Jeremy M Sivak, Izzy Livne-Bar; Lipoxin B4, a Novel Neuroprotectant for the Inner Retina.. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2575.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the in vivo neuroprotective effect of lipoxin B4 (LXB4) in a rat model of chronic ocular hypertension.

Methods : Monocular chronic ocular hypertension was induced in rats (male Long Evans, 3 months) using the circumlimbal suture model. They were randomly assigned for LXB4 (n=9) or vehicle (phosphate-buffered saline, n=9) treatment, both locally (eye drop, 100 ng/eye) and systemically (1 µg/rat, IP), from week 8 (3 times a week, every other day). Intraocular pressure (IOP), retinal function (electroretinogram, ERG) and structure (optical coherence tomography, OCT) were monitored in both groups for 15 weeks. Retinal tissue was collected (whole-mount) at the end of 15 weeks and retinal ganglion cell (RGC) counts were determined following Brn3a immunostaining.

Results : LXB4 had no effect on IOP (LXB4 18.4 ± 0.9 mmHg vs vehicle 20.6 ± 2.5 mmHg; week 15). RGC function as measured by pSTR ERG, was reduced by -37.8% ± 10.9% in the vehicle group and -24.1% ± 12.9% in the LXB4 treatment group (p=0.03), at week 15. Retinal nerve fiber layer (RNFL) thickness was reduced by -35.7% ± 7.7% in the vehicle group compared to -18.2% ± 10.9% (p=0.02) in the LXB4 group, at week 15. RGC counts showed increased loss in the vehicle group (-33.6% ± 2.6%) compared to the LXB4 group (-17.2% ± 3.6%; p<0.001), at week 15.

Conclusions : LXB4 was protective of the inner retina in a chronic IOP rat model. This novel and previously unknown neuroprotective action was independent of IOP, which was unaffected by the administration of LXB4.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×